Dr. Krishna Gundabolu, MBBS
Claim this profileUniversity of Nebraska
Area of expertise
Burkitt's Leukemia
Krishna Gundabolu, MBBS has run 3 trials for Burkitt's Leukemia. Some of their research focus areas include:
Acute Lymphoblastic Leukemia
Krishna Gundabolu, MBBS has run 2 trials for Acute Lymphoblastic Leukemia. Some of their research focus areas include:
Affiliated Hospitals
Nebraska Medicine-Village Pointe
University Of Nebraska Medical Center
Clinical Trials Krishna Gundabolu, MBBS is currently running
Inotuzumab Ozogamicin + Chemotherapy
for Leukemia
This phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a chemotherapy drug called ozogamicin. Inotuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD22 receptors, and delivers ozogamicin to kill them. Chemotherapy drugs, such as \[intervention\], work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving inotuzumab ozogamicin with chemotherapy may work better in treating young adults with B acute lymphoblastic leukemia.
Recruiting
2 awards
Phase 3
3 criteria
Inotuzumab + Blinatumomab
for Acute Lymphoblastic Leukemia
This phase II trial studies how well inotuzumab ozogamicin and blinatumomab with or without ponatinib work in treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is newly diagnosed, has come back after a period of improvement (recurrent), or does not respond to treatment (refractory). Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a chemotherapy drug, called ozogamicin. Inotuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD22 receptors, and delivers ozogamicin to kill them. Blinatumomab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Ponatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving inotuzumab ozogamicin and blinatumomab with or without ponatinib may be effective in treating patients with newly diagnosed, recurrent or refractory CD22 positive B-lineage acute lymphoblastic leukemia.
Recruiting
1 award
Phase 2
10 criteria
More about Krishna Gundabolu, MBBS
Clinical Trial Related
9 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Krishna Gundabolu, MBBS has experience with
- Inotuzumab Ozogamicin
- WU-CART-007
- Allopurinol
- Bone Marrow Aspiration And Biopsy
- Cyclophosphamide
- Cytarabine
Breakdown of trials Krishna Gundabolu, MBBS has run
Burkitt's Leukemia
Acute Lymphoblastic Leukemia
Acute T-Cell Leukemia
Lymphoblastic Lymphoma
T-Cell Lymphoblastic Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Krishna Gundabolu, MBBS specialize in?
Krishna Gundabolu, MBBS focuses on Burkitt's Leukemia and Acute Lymphoblastic Leukemia. In particular, much of their work with Burkitt's Leukemia has involved CD22 positive patients, or patients who are Philadelphia chromosome/BCR-ABL1 negative.
Is Krishna Gundabolu, MBBS currently recruiting for clinical trials?
Yes, Krishna Gundabolu, MBBS is currently recruiting for 2 clinical trials in Omaha Nebraska. If you're interested in participating, you should apply.
Are there any treatments that Krishna Gundabolu, MBBS has studied deeply?
Yes, Krishna Gundabolu, MBBS has studied treatments such as Inotuzumab Ozogamicin, WU-CART-007, Allopurinol.
What is the best way to schedule an appointment with Krishna Gundabolu, MBBS?
Apply for one of the trials that Krishna Gundabolu, MBBS is conducting.
What is the office address of Krishna Gundabolu, MBBS?
The office of Krishna Gundabolu, MBBS is located at: University of Nebraska, Omaha, Nebraska 68198 United States. This is the address for their practice at the University of Nebraska.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.